Ocular Hypertension - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 137
Inquire Before Buying

Ocular Hypertension - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘Ocular Hypertension - Pipeline Review, H2 2016', provides an overview of the Ocular Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension

- The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects

- The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Ocular Hypertension - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Ocular Hypertension Overview 11
Therapeutics Development 12
Pipeline Products for Ocular Hypertension - Overview 12
Pipeline Products for Ocular Hypertension - Comparative Analysis 13
Ocular Hypertension - Therapeutics under Development by Companies 14
Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes 16
Ocular Hypertension - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Ocular Hypertension - Products under Development by Companies 20
Ocular Hypertension - Products under Investigation by Universities/Institutes 22
Ocular Hypertension - Companies Involved in Therapeutics Development 23
Aerie Pharmaceuticals, Inc. 23
Allergan Plc 24
Amakem NV 25
Bausch & Lomb Incorporated 26
Can-Fite BioPharma Ltd. 27
D. Western Therapeutics Institute, Inc. 28
F. Hoffmann-La Roche Ltd. 29
Inotek Pharmaceuticals Corporation 30
Ironwood Pharmaceuticals, Inc. 31
Kowa Company, Ltd. 32
Laboratoires Thea S.A. 33
Laboratorios Sophia S.A. de C.V. 34
Lee's Pharmaceutical Holdings Limited 35
Lexicon Pharmaceuticals, Inc. 36
NicOx S.A. 37
Ocular Therapeutix, Inc. 38
Otsuka Holdings Co., Ltd. 39
pSivida Corp. 40
Sanofi 41
Santen Pharmaceutical Co., Ltd. 42
Senju Pharmaceutical Co., Ltd. 43
Sylentis S.A.U. 44
ViSci Ltd. 45
Ocular Hypertension - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
(bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
(bimatoprost + timolol maleate) - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
(carteolol hydrochloride + latanoprost) - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
(latanoprost + netarsudil mesylate) - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
(latanoprost + timolol maleate) - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
(latanoprost + trabodenoson) - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
AMA-0076 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
bamosiran - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
bimatoprost - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
bimatoprost SR - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
DE-117 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
H-1129 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
IWP-953 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
latanoprost - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
latanoprost - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
latanoprost SR - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
latanoprost SR - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
latanoprost SR - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
latanoprostene bunod - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
levobetaxolol hydrochloride - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
LX-7101 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
MGV-354 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
NCX-1653 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
NCX-470 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
NCX-667 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
netarsudil mesylate - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
OPA-6566 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
piclidenoson - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
PRO-067 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
RG-4929 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
ripasudil - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
RO-5093151 - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
SAR-366234 - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
Sepetaprost - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
SNJ-1656 - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
trabodenoson - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
travoprost SR - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
travoprost XR - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
Ocular Hypertension - Dormant Projects 122
Ocular Hypertension - Discontinued Products 124
Ocular Hypertension - Product Development Milestones 125
Featured News & Press Releases 125
Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02% 125
May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 125
Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension 126
Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 126
Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension 127
Mar 28, 2016: Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 128
Mar 17, 2016: Aerie Pharmaceuticals Reports Update on Positive Safety Results for Rhopressa QD (netarsudil ophthalmic solution) 0.02% 128
Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 129
Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 130
Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2 131
Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension 131
Oct 22, 2015: Ocular Therapeutix Reports on Topline Results of Phase 2b Glaucoma Clinical Trial 132
Oct 01, 2015: New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension 134
Sep 24, 2015: Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa 134
Sep 21, 2015: Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137

List of Tables
Number of Products under Development for Ocular Hypertension, H2 2016 12
Number of Products under Development for Ocular Hypertension - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 23
Ocular Hypertension - Pipeline by Allergan Plc, H2 2016 24
Ocular Hypertension - Pipeline by Amakem NV, H2 2016 25
Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H2 2016 26
Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H2 2016 27
Ocular Hypertension - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 28
Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 29
Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 30
Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 31
Ocular Hypertension - Pipeline by Kowa Company, Ltd., H2 2016 32
Ocular Hypertension - Pipeline by Laboratoires Thea S.A., H2 2016 33
Ocular Hypertension - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016 34
Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 35
Ocular Hypertension - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 36
Ocular Hypertension - Pipeline by NicOx S.A., H2 2016 37
Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H2 2016 38
Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 39
Ocular Hypertension - Pipeline by pSivida Corp., H2 2016 40
Ocular Hypertension - Pipeline by Sanofi, H2 2016 41
Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 42
Ocular Hypertension - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 43
Ocular Hypertension - Pipeline by Sylentis S.A.U., H2 2016 44
Ocular Hypertension - Pipeline by ViSci Ltd., H2 2016 45
Assessment by Monotherapy Products, H2 2016 46
Assessment by Combination Products, H2 2016 47
Number of Products by Stage and Target, H2 2016 49
Number of Products by Stage and Mechanism of Action, H2 2016 51
Number of Products by Stage and Route of Administration, H2 2016 53
Number of Products by Stage and Molecule Type, H2 2016 55
Ocular Hypertension - Dormant Projects, H2 2016 122
Ocular Hypertension - Dormant Projects (Contd..1), H2 2016 123
Ocular Hypertension - Discontinued Products, H2 2016 124

List of Figures
Number of Products under Development for Ocular Hypertension, H2 2016 12
Number of Products under Development for Ocular Hypertension - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Products, H2 2016 19
Assessment by Monotherapy Products, H2 2016 46
Assessment by Combination Products, H2 2016 47
Number of Products by Top 10 Targets, H2 2016 48
Number of Products by Stage and Top 10 Targets, H2 2016 48
Number of Products by Top 10 Mechanism of Actions, H2 2016 50
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 50
Number of Products by Routes of Administration, H2 2016 52
Number of Products by Stage and Routes of Administration, H2 2016 52
Number of Products by Molecule Types, H2 2016 54
Number of Products by Stage and Molecule Types, H2 2016 54
  • Ophthalmology Drug Development Pipeline Review, 2016
    Published: 01-Dec-2016        Price: US 3995 Onwards        Pages: 633
    Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number of treatments approved in ophthalmology, there are currently no curative therapies for any of these indications. In particular, there are strong unmet needs within age-related macular degeneration and glaucoma, which can lead to blindness if not adequately treated. Although there......
  • Global Dry Eye Syndrome Drug Market Research Report 2016
    Published: 30-Nov-2016        Price: US 2900 Onwards        Pages: 102
    Notes: Production, means the output of Dry Eye Syndrome Drug Revenue, means the sales value of Dry Eye Syndrome Drug This report studies Dry Eye Syndrome Drug in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Allergan - Novartis - Santen - Shire - Otsuka ......
  • Global Conjunctivitis Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 30-Nov-2016        Price: US 3480 Onwards        Pages: 118
    Conjunctivitis, or inflammation of the conjunctiva, is a general term that refers to a diverse group of diseases/disorders that affect the conjunctiva primarily. Most varieties of conjunctivitis are self-limited, but some progress and may cause serious ocular and extraocular complications.Conjunctivitis is more commonly referred to as pink eye. The whites of the eyes appear pink or red when the conjunctiva (the transparent membrane which lines part of the eyeball) becomes inflamed or infected......
  • Global Optic Neuritis Market Research Report 2016
    Published: 17-Nov-2016        Price: US 2900 Onwards        Pages: 103
    Notes: Production, means the output of Optic Neuritis Revenue, means the sales value of Optic Neuritis This report studies Optic Neuritis in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Sicor Societa' Italiana Corticosteroidi S.R.L - Allergan Pharmaceuticals Ireland......
  • Macular Edema - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 63
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2016, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged bl......
  • Diabetic Retinopathy - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 237
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2016, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposi......
  • Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 136
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016, provides an overview of the Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline landscape.Dry atrophic macular degeneration is generally characterized by a slow but progressive visual loss. This is characterized by yellow spots under the retina, called drusen, which are accumulations of metabolic waste products. Symptoms include blurred o......
  • Retinal Vein Occlusion - Pipeline Review, H2 2016
    Published: 09-Nov-2016        Price: US 2000 Onwards        Pages: 76
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2016, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclero......
  • Global Assistive Technologies for Visual Impairment Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 08-Nov-2016        Price: US 3480 Onwards        Pages: 117
    Assistive Technologies for Visual Impairment is an umbrella term that includes assistive, adaptive, and rehabilitative devices for people with Visual Impairment and also includes the process used in selecting, locating, and using them. Scope of the Report: This report focuses on the Assistive Technologies for Visual Impairment in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market bas......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs